Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.

Polyclinique Lyon Nord90 enrolled

Overview

The hospital pharmacist plays a vital role at the time of the patient's first prescription in a healthcare facility, to inform the patient about his or her new therapy and create a link between the hospital and the patient's home pharmacy, so that the patient can continue to receive care at home. It is also essential that the hospital pharmacy and the patient's local pharmacy work together within a reasonable timeframe. This will help improve patient care and treatment follow-up, detect any undesirable effects and optimize their management.. The aim of this prospective interventional study is to measure the benefits of pharmaceutical monitoring in healthcare institutions at the initiation of oral therapy on patient compliance, side-effect management and adherence, in comparison with patients without this monitoring. The primary endpoint is compliance with the Girerd questionnaire.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Neoplasm

Interventions

Pharmaceutical consultation and follow-upPROCEDURE

After the first prescription and at the treatment renewal date (+/- 2 days), the hospital pharmacist will contact the dispensing pharmacist to inform him/her of the patient's treatment, and then as part of the follow-up to detect any problems with treatment compliance (non-renewal of treatment by the patient, lack of follow-up, complaints of adverse effects by the patient). These events will be recorded in the observation book.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient suffering from an oncological pathology (excluding hematological malignancies) * Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments). * Patient who has not yet started treatment or who has started treatment less than 30 days * Patient with continuation of oral therapy dispensed in pharmacies Exclusion Criteria: * Patients suffering from hematological malignancies * Patient living in an institution or hospital * Patient under treatment for more than 30 days * Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment) * Patient whose treatment after initiation is not dispensed in a pharmacy

Outcomes

Primary Outcomes

Observance

The measurement of the primary endpoint is based on the use of a validated scale for assessing medication compliance: the Girerd scale. This is a 6-question questionnaire with a binary yes/no response. The score ranges from 0 to 6, with a "yes" worth 1 point.

Time frame: 3 months and 6 months after treatment initiation